February 10, 2021 – UBS Investment Bank today announced the recent listing of seven new 2x Leveraged US Factor ETNs specified in the table below.
ETN Ticker | ETN Ticker | ETN Name | ETN Name | ETN CUSIP | ETN CUSIP | Underlying Index Bloomberg Ticker | Underlying Index Bloomberg Ticker |
---|---|---|---|---|---|---|---|
ETN Ticker | SCDL | ETN Name | ETRACS 2x Leveraged US Dividend Factor TR ETN | ETN CUSIP | 90278V206 | Underlying Index Bloomberg Ticker | DJUSDIVT |
ETN Ticker | IWFL | ETN Name | ETRACS 2x Leveraged US Growth Factor TR ETN | ETN CUSIP | 90278V305 | Underlying Index Bloomberg Ticker | RU10GRTR |
ETN Ticker | IWML | ETN Name | ETRACS 2x Leveraged US Size Factor TR ETN | ETN CUSIP | 90278V404 | Underlying Index Bloomberg Ticker | RU20INTR |
ETN Ticker | IWDL | ETN Name | ETRACS 2x Leveraged US Value Factor TR ETN | ETN CUSIP | 90278V107 | Underlying Index Bloomberg Ticker | RU10VATR |
ETN Ticker | USML | ETN Name | ETRACS 2x Leveraged MSCI US Minimum Volatility Factor TR ETN | ETN CUSIP | 90278V701 | Underlying Index Bloomberg Ticker | M00IMV$T |
ETN Ticker | MTUL | ETN Name | ETRACS 2x Leveraged MSCI US Momentum Factor TR ETN | ETN CUSIP | 90278V602 | Underlying Index Bloomberg Ticker | M2US000$ |
ETN Ticker | QULL | ETN Name | ETRACS 2x Leveraged MSCI US Quality Factor TR ETN | ETN CUSIP | 90278V503 | Underlying Index Bloomberg Ticker | M2USSNQ |
About ETRACS
ETRACS ETNs are senior unsecured notes issued by UBS AG, are traded on NYSE Arca, and can be bought and sold through a broker or financial advisor. An investment in ETRACS ETNs is subject to a number of risks, including the risk of loss of some or all of the investor’s principal, and is subject to the creditworthiness of UBS AG. Investors are not guaranteed any coupon or distribution amount under the ETNs. We urge you to read the more detailed explanation of risks described under “Risk Factors” in the applicable prospectus supplement, or product supplement and pricing supplement, as applicable, for the ETRACS ETN.
UBS AG has filed a registration statement (including a prospectus and supplements thereto) with the Securities and Exchange Commission, or SEC, for the offerings of securities to which this communication relates. Before you invest, you should read the prospectus, along with the applicable prospectus, pricing, or product supplement to understand fully the terms of the securities and other considerations that are important in making a decision about investing in the ETRACS. The applicable offering document for each ETRACS may be obtained by clicking the Prospectus Supplement hyperlink above. You may also get these documents without cost by visiting EDGAR on the SEC website at www.sec.gov. The securities related to the offerings are not deposit liabilities and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency of the United States, Switzerland or any other jurisdiction.
About UBS
UBS provides financial advice and solutions to wealthy, institutional and corporate clients worldwide, as well as private clients in Switzerland. UBS's strategy is centered on our leading global wealth management business and our premier universal bank in Switzerland, enhanced by Asset Management and the Investment Bank. The bank focuses on businesses that have a strong competitive position in their targeted markets, are capital efficient, and have an attractive long-term structural growth or profitability outlook.
UBS is present in all major financial centers worldwide. It has offices in more than 50 regions and locations, with about 31% of its employees working in the Americas, 32% in Switzerland, 19% in the rest of Europe, the Middle East and Africa and 18% in Asia Pacific. UBS Group AG employs over 67,000 people around the world. Its shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE).
This material is issued by UBS AG and/or any of its subsidiaries and/or any of its affiliates ("UBS"). Products and services mentioned in this material may not be available for residents of certain jurisdictions. Past performance is not necessarily indicative of future results. Please consult the restrictions relating to the product or service in question for further information. Activities with respect to US securities are conducted through UBS Securities LLC, a US broker/dealer. Member of SIPC (http://www.sipc.org/).
ETRACS ETNs are sold only in conjunction with the relevant offering materials. UBS has filed a registration statement (including a prospectus, as supplemented by the applicable prospectus supplement, or product supplement and pricing supplement, for the offering of the ETRACS ETNs) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read these documents and any other documents that UBS has filed with the SEC for more complete information about UBS and the offering to which this communication relates. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you can request the applicable prospectus supplement, or product supplement and pricing supplement, by calling toll-free (+1-877-387 2275). In the US, securities underwriting, trading and brokerage activities and M&A advisor activities are provided by UBS Securities LLC, a registered broker/dealer that is a wholly owned subsidiary of UBS AG, a member of the New York Stock Exchange and other principal exchanges, and a member of SIPC. UBS Financial Services Inc. is a registered broker/dealer and affiliate of UBS Securities LLC.
The IWFL, IWML and IWDL ETNs (the “ETNs”) have been developed solely by UBS. The ETNs are not in any way connected to or sponsored, endorsed, sold or promoted by the London Stock Exchange Group plc and its group undertakings (collectively, the “LSE Group”). FTSE Russell is a trading name of certain of the LSE Group companies. All rights in the FTSE Russell Indices (the “Indices”) vest in the relevant LSE Group company which owns the Index. “Russell®” and “FTSE Russell®” are a trademarks of the relevant LSE Group company and are used by any other LSE Group company under license. The Index is calculated by or on behalf of FTSE International Limited or its affiliate, agent or partner. The LSE Group does not accept any liability whatsoever to any person arising out of (a) the use of, reliance on or any error in the Index or (b) investment in or operation of the ETNs. The LSE Group makes no claim, prediction, warranty or representation either as to the results to be obtained from the ETNs or the suitability of the Index for the purpose to which it is being put by UBS.
The securities referred to herein are not sponsored, endorsed, issued, sold or promoted by MSCI, and MSCI bears no liability with respect to any such securities or any index on which such securities are based. The respective ETN prospectus contains a more detailed description of the limited relationship MSCI has with UBS.
The Dow Jones US Dividend 100 TR USD Index (“Index”) is a product of S&P Dow Jones Indices LLC and has been licensed for use by UBS AG. Copyright © 2021 S&P Dow Jones Indices LLC (“S&P DJI”), a division of S&P Global. All rights reserved. S&P® is a registered trademark of Standard & Poor’s Financial Services LLC (“S&P”) and Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”). UBS’s ETRACS Exchange Traded Notes based on the Index are not sponsored, endorsed, marketed or sold by S&P DJI, S&P, Dow Jones, their affiliates or third party licensors and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the Indexes.
UBS specifically prohibits the redistribution or reproduction of this material in whole or in part without the prior written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect.
© UBS 2021. The key symbol, UBS and ETRACS are among the registered and unregistered trademarks of UBS. Other marks may be trademarks of their respective owners. All rights reserved.
Media contact
Christina Aquilina
1-212-713-4488
Email
Institutional Investor contact1
+1-877-387 2275